Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nihon Koden To Voluntarily Repair 85,000 AEDs

This article was originally published in PharmAsia News

Executive Summary

Nihon Koden April 28 announced a plan to repair 85,000 automatic external defibrillators

Nihon Koden April 28 announced a plan to repair 85,000 automatic external defibrillators.

The company said the affected products, CardioLife ADE-9100 and 9200 were manufactured by Cardiac Science of U.S. and imported and marketed in Japan by Nihon Koden. According to the company, the devices may mistakenly turn on the "need attention" light, and will not deliver life-saving shocks to patients. One case has been reported in Japan where the AED stopped working, but no severe adverse effects have been reported. Nihon Koden has notified the medical facilities that purchased the devices and will visit them to make repairs. (Click here for more - Japanese language)

"Nihon Koden voluntarily Repairs 85,000 AEDs" - CB News (4/30/2010)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel